Aims/hypothesis The aim of the study was to investigate the association between vitamin D intake and status and the risk of islet autoimmunity (IA) 
Introduction
Type 1 diabetes is an autoimmune disease mediated by T helper cells. During the process preceding clinical diabetes, the immune system has a bias towards a Th1 response wherein autoimmunity exists but there are no overt clinical signs of type 1 diabetes. Vitamin D has been examined as a potentially protective factor because it plays an active role in the regulation of the immune system [1] . Mechanistically, vitamin D has been shown to shift the balance of the body's T cell response towards downregulation of the Th1 immune response [2] . Both in vitro studies and animal studies have found that vitamin D stimulates a Th2 response [3] [4] [5] .
A number of epidemiological reports suggest a role for vitamin D in the pathogenesis of type 1 diabetes. A case-control study found that fish oil supplementation in infancy was associated with a lower risk of type 1 diabetes [6] . As fish oils contain both n-3 fatty acids and vitamin D, it is not possible to attribute this association to one specific component. Two additional studies found that diabetic children were less likely to have received vitamin D supplements during infancy than non-diabetic children [7, 8] . Vitamin D intake from either foods [9] or supplements [10] during pregnancy was associated with a lower risk of islet autoimmunity (IA) in the offspring, although a third study was not consistent with these findings [11] . While these studies have examined vitamin D exposures very early in life, with conflicting results, it is not known whether later childhood exposures to vitamin D are associated with the risk of IA or type 1 diabetes. Moreover, reliance on intake alone to assess exposure may not be an accurate measure of vitamin D status, as this does not account for non-dietary sources of vitamin D.
The data regarding 25(OH)D levels have been inconsistent. Three cross-sectional studies have shown lower 25 (OH)D levels among newly diagnosed type 1 diabetes cases compared with controls [12] [13] [14] , although another found no association between serum 25(OH)D and type 1 diabetes [15] . In addition, two clinical trials reported no effect of 1α,25-dihydroxyvitamin D 3 supplementation on sustained insulin production among persons with newonset type 1 diabetes [16, 17] . However, no inferences can be made from these studies about 25(OH)D before onset of disease.
The purpose of this study was to examine the association between two assessments of vitamin D: reported dietary intake of vitamin D and plasma 25(OH)D measured throughout childhood; and the time to development of IA, and the progression to type 1 diabetes in IA-positive children.
Methods
In order to investigate the association between vitamin D, IA and type 1 diabetes, we performed a number of studies using cohorts derived from the Diabetes Autoimmunity Study in the Young (DAISY) population, as described below. Figure 1 is a flow chart that describes these studies and their respective study cohorts.
DAISY population
DAISY is a prospective study of two groups of children at increased risk of developing type 1 diabetes. One group consists of first-degree relatives of patients with type 1A diabetes mellitus, recruited between birth and 8 years of age. The second group consists of babies born at St Joseph's Hospital in Denver, CO, USA, whose umbilical cord blood was screened for diabetes-susceptibility alleles in the HLA region. The St Joseph's Hospital newborn population is representative of the general population of the Denver metropolitan area. The details of the newborn screening [18] and follow-up [19] have been published elsewhere. Cord blood or the first available blood sample (depending on enrolment group) is sent to Roche Molecular Systems (Alameda, CA, USA) for PCR-based HLA class II typing. Recruitment took place between 1993 and 2006. Written informed consent was obtained from the parents of study participants. The Colorado Multiple Institutional Review Board approved all study protocols.
Measurement of autoantibodies
Autoantibodies were tested at 9, 15 and 24 months, and annually thereafter. Radioimmunoassays were used to measure serum autoantibodies to insulin, GAD 65 and IA-2 (BDC512), as previously described [20] [21] [22] [23] , with rigorous duplicate testing and confirmation of all positive and a subset of negative results. The cut-off for positivity was established as the 99th centile of healthy controls. If a participant tested autoantibody positive, they were put on an accelerated testing schedule of every 3-6 months.
Measurement of dietary intake of vitamin D
Current dietary intake of vitamin D in international units (IU) was assessed using one of two instruments. For children aged 2-9 years of age, parents filled out a food frequency questionnaire (FFQ) (Nutrition Questionnaire Service Center, Boston, MA, USA) on the child's behalf annually. Starting between the ages of 10 and 12 years, children were asked to recall their own diets and complete the youth/adolescent questionnaire (YAQ), a food frequency questionnaire geared toward adolescents [24, 25] that is based on the FFQ. Both surveys collected the average food consumption over the course of the previous year, using structured responses regarding how often a child consumes commonly sized portions (example: one slice of bread), with the response options ranging from 'never' to '6+ servings per day'. Fluid cow's milk is a major source of dietary vitamin D in US children, because it is routinely fortified to a level of 400 IU per 0.95 l. We conducted an instrument-comparison study in our DAISY population, in which we determined that data from these two instruments may be combined when an instrument indicator variable (i.e. type of food frequency questionnaire [FFQ vs YAQ]) was included in the model [26] . The FFQ has been validated against multiple 24 h recalls [27] and has been found to correlate with micronutrient [28] and fatty acid [29] biomarkers in our population. Dietary data were linked to an autoantibody measurement if the 1-year time period of the questionnaire encompassed the time directly preceding the clinic visit at which the autoantibody was measured.
Measurement of plasma 25(OH)D levels
Blood was drawn and kept from light at all times during processing. Plasma was separated immediately, snap-frozen in liquid nitrogen, and stored at −70°C until sent to the The outcome for Study 1 was the development of IA, which is defined as testing positive for at least one of three autoantibodies (described above) on at least two consecutive visits less than 6 months apart. The median number of clinical visits per child at which autoantibody status was ascertained was seven. The median time that elapsed between clinical visits was 356 days. As of February 2011, 198 children developed IA during follow-up of 2,644 DAISY children; however, not all of these children completed a diet survey or had a plasma sample for the measurement of 25(OH)D before their first positive visit (Fig. 1 childhood was associated with increased risk of IA. This study was conducted using all DAISY children who had completed at least one dietary questionnaire before their first autoantibody positive visit (n=1,875). The outcome is the development of IA (n=123). We had multiple measures of vitamin D intake before and including the first IA positive visit, with 203 children with one measure, 210 children with two, 177 children with three, 175 children with four, 187 children with five, 183 children with six, 148 children with seven, 119 children with eight, 93 children with nine, and 380 children with ten or more measures.
All analyses were conducted in SAS for Windows Version 9.2 (SAS Institute, Cary, NC, USA). Using proportional hazards analysis, HRs and 95% CI were estimated for the risk of IA for a SD difference in vitamin D intake. All SDs used for this standardisation technique are listed in the footnote of Table 3 . As vitamin D intake was measured longitudinally, we treated it as time-varying in our analyses, such that intake could vary with the clinical visits and reflect change over time in children who were still at risk of IA at a given event time.
All models were adjusted for family history of type 1 diabetes, HLA-DR3/4 DQB1*0302 genotype, average daily dietary energy intake, and type of survey completed (FFQ vs YAQ). In addition, we considered sex, ethnicity (nonHispanic white vs other), maternal age and maternal education as potential covariates and retained them if they significantly contributed to the model (at p<0.05).
25(OH)D and risk of IA (Study 1b)
Study 1b used a casecohort design to investigate whether lower plasma 25(OH)D or vitamin D insufficiency during childhood was associated with increased risk of the development of IA. To conduct the case-cohort study, a representative sample of children was selected from the eligible pool via stratified random sampling based on HLA-DR genotype and family history of type 1 diabetes. On the basis of availability of biological samples and timing of entry into the study, 1,433 DAISY children were eligible for selection, and, of these, we selected 380 children for this subcohort. During follow-up of the subcohort, 20 children developed IA. We supplemented this with 68 IA-positive children who developed in DAISY outside of this subcohort, and who had 25(OH)D measurements before the development of autoantibodies. Therefore 88 children with IA and 353 IA negative children were included in this analysis. The number of IA-positive children in this analysis (n=88) is less than the overall number in DAISY (n=198) because 110 children developed IA before we began the protocol of collecting plasma for measurement of 25(OH)D. Electronic supplementary material (ESM) Table 1 shows that the characteristics of the IA-positive children included in the case-cohort analyses are similar to those of the IA-positive children who were not included because of missing 25(OH)D. We were able to measure 25(OH)D in these children after they became IA positive and therefore could include them in Study 2 (described below).
HR and CI were estimated for the risk of IA for a SD difference in 25(OH)D. 25(OH)D was included in the model as a time-varying covariate. To account for the sampling of the case-cohort design, the analyses were weighted using the Barlow method [30] and a SAS macro developed by Ichikawa and Barlow [31] (http://lib.stat.cmu. edu/general/robphreg, accessed 29 July 2011).
Recognising that the relationship between vitamin D status and IA risk may not be linear, we analysed 25(OH)D both as a continuous variable and as a dichotomous vitamin D inadequacy variable, using the cut-off point of 50 nmol/l, as recommended in the recent Institute of Medicine report [32] .
All models were adjusted for family history of type 1 diabetes and HLA-DR3/4, DQB1*0302 genotype. Ethnicity, month of blood draw (May-October vs November-April), sex, maternal age and maternal education were considered as potential covariates and retained if they significantly contributed to the model (at p<0.05).
25(OH)D at 9 months of age and risk of IA (Study 1c)
In order to examine whether vitamin D status during infancy was specifically associated with risk of IA, we analysed the 128 children from Study 1b who had a 25(OH)D measurement at their 9 month clinic visit. Thirty of these children subsequently developed IA, and of these, six went on to develop type 1 diabetes. We treated the 9 month 25 (OH)D as fixed in the proportional hazards model. We adjusted for family history of type 1 diabetes and HLA-DR3/4, DQB1*0302 genotype. Month of blood draw (May-October vs November-April), sex, maternal age and maternal education were considered as potential covariates and retained if they significantly contributed to the model (at p<0.05). The outcome in Study 2 is physician-diagnosed type 1 diabetes, and was defined as a random blood glucose >11.1 mmol/l and/or a HbA 1c >6.3% (45 mmol/mol) with clinical symptoms of diabetes. We followed 198 IA-positive children; 62 developed type 1 diabetes during follow-up (Fig. 1) .
Vitamin D intake and the risk of type 1 diabetes in IA-positive children (Study 2a) Study 2a investigated whether lower vitamin D intake increased the risk of type 1 diabetes The potential predictors of 25(OH)D levels that were considered were year and month of sample collection, age of the study participant, sex, ethnicity, vitamin D intake, maternal age and maternal education. Of the 448 children in the case-cohort population (as described in Study 1b above), 47 were excluded because they did not have dietary intake data, leaving 401 children, 85 of whom subsequently developed IA for these longitudinal analyses (Fig. 1) . Data from visits after the child became IA positive were excluded.
We analysed the relationship between 25(OH)D and correlates using a linear mixed modelling approach [33] . The procedure discussed by Cnaan et al. [34] was used to determine best fit polynomials for both the fixed and random effects of month of blood draw. These models distinguish variability between participants and variability between repeated measurements over time within participants. The between-participant covariance matrices were restricted to be positive definite. We first developed a model that describes the variation of 25(OH)D on the basis of the month the sample was collected to capture seasonal variation. We then added the remaining variables to this model. The mixed model provides a regression coefficient, a standard error and p value for each variable to indicate its contribution towards explaining 25(OH)D levels.
BMI was initially included in the model and was marginally significantly associated with 25(OH)D in our population (p=0.056). However, because DAISY did not collect height before the age of 2 years, the early visits had to be excluded from the analysis because of missing BMI data. As the inclusion of BMI in this model did not substantially alter the estimate for the IA status variable, we decided to exclude BMI from our final model so that we could examine the association between 25(OH)D and IA status at very young ages. Table 3 .
Study 1: analysis of vitamin D and the risk of IA After adjustment for having a first-degree relative with type 1 diabetes, HLA-DR3/4, DQB1*0302 genotype, energy intake and the type of survey filled out (FFQ vs YAQ), intakes of vitamin D from all sources, from foods only, and from supplements only were not associated with the risk of IA (Study 1a in Table 3 ).
Neither 25(OH)D level nor vitamin D insufficiency was associated with the risk of IA, after adjustment for family history of type 1 diabetes, HLA-DR3/4, DQB1*0302 genotype and ethnicity (Study 1b in Table 3 ).
Recognising that much of the previous literature had focused on vitamin D in infancy, we examined whether plasma 25(OH)D at 9 months was associated with the risk of IA. Neither 25(OH)D level nor vitamin D insufficiency at 9 months of age were associated with the risk of IA, after adjustment for family history of type 1 diabetes and HLA-DR3/4, DQB1*0302 genotype (Study 1c in Table 3 ).
Study 2: analysis of vitamin D and risk of type 1 diabetes in IA-positive children
We then examined whether vitamin D may play a role in the progression to type 1 diabetes in children who are autoantibody positive. After adjustment for family history of type 1 diabetes, HLA-DR3/4, DQB1*0302 genotype, the type of survey completed, energy intake and age at first IA positivity, vitamin D intake was not associated with the risk of type 1 diabetes (Study 2a in Table 3 ).
Neither 25(OH)D levels nor vitamin D insufficiency were associated with progression to type 1 diabetes in IA- [6] [7] [8] . Some caveats to this comparison include (1) our inability to examine a comparable vitamin D supplement variable because the infant supplements taken by DAISY children contained a number of vitamins besides vitamin D, (2) our inability to examine the outcome of type 1 diabetes, and (3) the relatively small number of infants in whom we measured 25(OH)D at 9 months of age. In our analysis of 25(OH)D levels at 9 months of age, the HR for IA was 1.16 for a SD increase in 25(OH)D. The 95% CI (0.69, 1.93) of this HR suggests that our data do not support an hypothesis that increased 25(OH)D levels at 9 months are strongly associated with decreased IA risk (as defined by HRs<0.69), although weaker associations cannot be excluded.
Negative results mandate consideration of whether noise in the exposure measure biased the association towards the null. We analysed predictors of 25(OH)D in our DAISY children and demonstrated that plasma 25(OH)D is associated with previously documented predictors of 25(OH)D in children [35] , suggesting that our measure of 25(OH)D is internally valid.
While there are additional hypotheses that remain to be tested, including the exact role of supplementation during infancy, and whether only very high levels of vitamin D are protective (or conversely, only extremely low levels are a risk), our study, which uses a powerful combination of prospectively collected reports of vitamin D intake and a biomarker of vitamin D status, does not support an association between a child's usual vitamin D intake or 25 (OH)D levels throughout childhood and the risk of IA or progression to type 1 diabetes, in children at increased risk of the disease. Contribution statement MS and JMN were involved in the conception and design of the study, the analysis and interpretation of the data, and drafting of the manuscript. HB, JS, KB, XY, AB, MH, TB, RJS, GE and HE were involved in analysis and interpretation of data, and critically revising the manuscript for important intellectual content. MR was involved in the conception and design of the study and critically revising the manuscript for important intellectual content. All authors gave final approval of the version to be published.
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